Evaluating Embolization Using SQUID 12 and SQUID 18 for Treatment of Chronic Resistant Migraine
Led by Vedanta University Clinic · Updated on 2026-09-11
30
Participants Needed
1
Research Sites
56 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of embolization of the middle meningeal artery MMA using non-adhesive materials SQUID 12 and SQUID 18 as a treatment for patients with chronic resistant migraine. This study aims to understand how this procedure impacts the number of migraine days over time in adults aged 21 to 70 who have experienced migraines resistant to other treatments.
Participants receive total endovascular embolization of the frontal and parietal branches, and sometimes the occipital branch, of the MMA to reduce migraine symptoms. If the migraine pain is on one side, only that sides artery is embolized if on both sides, both arteries are treated. The procedure uses specific liquid embolic agents and is followed by a monitoring period lasting up to 12 months.
During the study, participants track the number of migraine and headache days using diaries and scales over several intervals up to one year after the procedure. Researchers assess headache intensity, associated symptoms, and quality of life using standardized tools like the HIT-6 and MIDAS scales. Safety and changes in migraine frequency and severity are closely monitored throughout the year following treatment.
CONDITIONS
Brief Title
CHROnic Migraine Embolization
Research Team
A
Andrey E Petrov, MD, PhD
A
Andrey S Dakovskiy, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosed with chronic migraine for at least 12 months
Migraine resistant to treatment as defined by European Headache Federation criteria for at least 6 months
At least 14 headache days in 28 days screening, with 8 migraine days
History of migraine resistant to both drug and non-drug prevention and treatment
Headache intensity of 5 or higher on a 10-point scale during migraine days in screening
No improvement from previous botulinum toxin therapy
Agreement to use effective contraception and not donate eggs or sperm during the study (for participants with reproductive potential)
You will not qualify if you...
Contraindications to middle meningeal artery embolization
Allergic reactions to contrast agents used in embolization procedures
History of cerebral vascular malformations, brain aneurysms, tumors, hydrocephalus, arachnoiditis, cerebrospinal fluid disorders, skull base deformities, severe brain injuries, or artery stenosis/occlusion
History of skull base fractures or neurosurgical operations
Mental illness affecting condition assessment or study participation
History of hyperthyroidism, diabetes, or other endocrine disorders interfering with study
History or current drug addiction or alcoholism
Medication-induced headache within 3 months before screening
Other chronic headache types within 12 months before screening
Inability to distinguish migraine headaches from others
Presence of migraine complications like status migrainosus or persistent aura
Body mass index below 18.5 or above 39.9 kg/m2
Migraine onset after age 50
Metabolic syndrome or cachexia
Severe cardiovascular diseases, including heart failure, arrhythmias, valve diseases, uncontrolled hypertension, embolism, or vein thrombosis
Varicose veins or history of vein thrombosis
Ischemic heart disease or atherosclerosis
History of stroke or its consequences
Pregnancy or plans for pregnancy within 3 months
Atrial fibrillation or heart surgeries
Blood clotting disorders or recent anticoagulant use
Severe asthma or chronic obstructive pulmonary disease
Kidney or liver insufficiency
Generalized pain syndrome or fibromyalgia
Combined oral contraceptive use with history of thrombosis
History of epilepsy or seizure disorders
Positive tests or history of HIV, hepatitis, or syphilis
Recent or current cancer
Other serious medical or psychological conditions affecting participation
Participation in other interventional clinical trials within 30 days
Inability to comply with study procedures or reading/writing difficulties
Employment or family relationship with study site or sponsor
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit
Treatment
Duration - 1 day
Participants receive embolization of the middle meningeal artery using SQUID 12 and SQUID 18 to treat chronic resistant migraine.
1 procedure visit
Follow-up
Duration - 12 months
Participants are monitored for migraine and headache days, headache intensity, and related symptoms for up to 12 months after treatment.
Multiple visits at 1, 2, 3, 6, 9, and 12 months post-treatment
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Randomized, Controlled Trial to Assess the MySalvia Neuromodulation System for Preventing Resistant Migraine in Adults
Safety and Feasibility Study of Bilateral Middle Meningeal Artery Embolization Using Onyx for Treatment-Resistant Chronic Migraine
Evaluating Embolization Using SQUID 12 and SQUID 18 for Treatment of Chronic Resistant Migraine
Study Comparing Myofascial Trigger Point Injection and Greater Occipital Nerve Block for Treating Chronic Migraine in Adults Aged 18 to 65
Observational Registry of Patient-Reported Outcomes After Middle Meningeal Artery Embolization for Migraine in Adults
Molecular Study of Migraine Patients and Healthy Controls by Measuring CGRP Levels in Saliva and Blood Tests for DNA and Hormones
Study of Brain and Psychological Traits Linked to Suggestibility in Adults With Chronic Migraine Not Responding to Treatment
Study of Combined CGRP Monoclonal Antibody and Onabotulinumtoxin A Therapy Compared to CGRP Monoclonal Antibody Alone for Preventing Chronic Migraine in Adults Aged 18 to 70
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Middle Meningeal Artery Embolization Using Non-Adhesive Liquid Embolic Agents for Chronic Resistant Migraine: Interim Feasibility and Safety Analysis of a Prospective Single-Arm Trial.
Andrey Petrov, Ruslan Sharshebaev, Gulmira Biialieva...